<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00799188</url>
  </required_header>
  <id_info>
    <org_study_id>2007.489/32</org_study_id>
    <nct_id>NCT00799188</nct_id>
  </id_info>
  <brief_title>CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial</brief_title>
  <acronym>CERTICOEUR</acronym>
  <official_title>CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart transplant is a recognized therapeutic strategy in refractory heart failure. Its&#xD;
      success is however hampered by severe cancer occurrence and recurrence. The new m-tor&#xD;
      inhibiting drugs Sirolimus and Everolimus have shown potential for reducing the incidence of&#xD;
      cancer in animal models. They are potent immunosuppressant, antiproliferative and&#xD;
      antiangiogenic drugs. This open labelled randomized multicenter study aims at evaluating the&#xD;
      beneficial antineoplastic effect of Everolimus in 159 heart transplant patients suffering of&#xD;
      recurrent skin cancer. Primary objective is to demonstrate a reduction in the number of new&#xD;
      skin cancers. Secondary end point will be time of recurrence, incidence of non skin cancer,&#xD;
      graft function following switch (including death), renal function evolution following&#xD;
      calcineurin inhibitors reduction or withdrawal, Everolimus tolerance profile, schemes of&#xD;
      calcineurin inhibitors reduction management in centers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Open labelled randomized Everolimus vs reduction of calcineurin inhibitors trial. 2:1&#xD;
           randomization design&#xD;
&#xD;
        -  October 10, 2008&#xD;
&#xD;
        -  159 patients (106 everolimus vs 53 calcineurin inhibitors reduction)&#xD;
&#xD;
        -  175 patients (117 vs 58)&#xD;
&#xD;
        -  X Not yet recruiting 0 recruiting 0 no longer recruiting&#xD;
&#xD;
        -  Number of skin tumors per patients requiring surgery with histology control within 2&#xD;
           years&#xD;
&#xD;
      Within 2 years of Follow up:&#xD;
&#xD;
        -  New skin cancer&#xD;
&#xD;
        -  Number of patients with new skin cancers&#xD;
&#xD;
        -  Time of recurrence&#xD;
&#xD;
        -  Number and histology of other types of skin cancer&#xD;
&#xD;
        -  Graft function (including acute rejection, graft loss, death)&#xD;
&#xD;
        -  Renal function evolution as assessed using Cockcroft creatinine clearance and&#xD;
           proteinuria&#xD;
&#xD;
        -  Adverse events and serious adverse events&#xD;
&#xD;
        -  Non skin cancer (Number and diagnostic)&#xD;
&#xD;
        -  Schemes of calcineurin inhibitors reduction/withdrawal&#xD;
&#xD;
        -  Immune response assessment through regulatory or effector function of blood and in situ&#xD;
           T lymphocytes at baseline and following immunosuppression switch&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of skin tumors per patients requiring surgery with histology control within 2 years</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>New skin cancer</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with new skin cancers</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of recurrence</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and histology of other types of skin cancer</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft function (including acute rejection, graft loss, death)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function evolution as assessed using Cockcroft creatinine clearance and proteinuria</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non skin cancer (Number and diagnostic)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schemes of calcineurin inhibitors reduction/withdrawal</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response assessment through regulatory or effector function of blood and in situ T lymphocytes at baseline and following immunosuppression switch</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">175</enrollment>
  <condition>Cardiac Transplantation</condition>
  <condition>Skin Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>reduction of immunosuppression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>switch to Everolimus : 50% reduction of calcineurin inhibitors (ciclosporine or tacrolimus)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Certican</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  First orthotopic heart transplant after 1st year&#xD;
&#xD;
          -  No rejection within previous 6 Months&#xD;
&#xD;
          -  Occurrence of squamous cell carcinoma, basal cell carcinoma, in situ carcinoma, Bowen&#xD;
             disease, premalignant keratosis&#xD;
&#xD;
          -  Recurrence of skin cancers leading to immunosuppressive regimen modifications&#xD;
&#xD;
          -  Removal of a skin lesion in the past three years&#xD;
&#xD;
          -  Above 18 yrs and under contraceptive drugs if applicable&#xD;
&#xD;
          -  Informed consent given&#xD;
&#xD;
          -  Health coverage ongoing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other non simultaneously transplanted organ&#xD;
&#xD;
          -  recent biopsy proven acute rejection&#xD;
&#xD;
          -  Proteinuria &gt; 1g/l&#xD;
&#xD;
          -  Ongoing infectious disease&#xD;
&#xD;
          -  HIV positivity, Chronic active Hepatitis B or C.&#xD;
&#xD;
          -  Abnormal blood tests: transaminases &gt;= 3UNL, Bilirubin &gt; 34 mmol.l, albumin&lt;35 g/l,&#xD;
             spontaneous INR &gt;1,3&#xD;
&#xD;
          -  Hemoglobin &gt;= 8 g/dl, White Blood Count&lt;= 2 giga/l, platelet count &lt;= 50 giga/l&#xD;
&#xD;
          -  Hypercholesterolemia&gt;= 9 mmol/l, hypertriglyceridemia &gt;= 8,5 mmol/l despite treatment&#xD;
&#xD;
          -  History of macrolid or mTor inhibitor intolerance&#xD;
&#xD;
          -  Previous cancer other than skin in the year prior to enrollment&#xD;
&#xD;
          -  Medical or surgical condition unsuitable for the trial&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Severe psychiatric disorder&#xD;
&#xD;
          -  Communication or language disability&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LAURENT SEBBAG, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HOSPICES CIVILS de LYON</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>November 26, 2008</study_first_submitted>
  <study_first_submitted_qc>November 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2008</study_first_posted>
  <last_update_submitted>December 11, 2013</last_update_submitted>
  <last_update_submitted_qc>December 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiac Transplantation</keyword>
  <keyword>Skin cancer</keyword>
  <keyword>Everolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

